Although metastasis or relapse is a leading cause of death for patients with gastric cancer, the hematogenous spread of cancer cells remains undetected at the time of initial therapy. The development of novel diagnostic molecular marker(s) to detect circulating gastric cancer cells is an issue of great clinical importance. We obtained peripheral blood samples from 10 patients with gastric cancer who underwent laparotomy and 4 healthy volunteers. Microarray analysis consisting of 30,000 genes or ESTs was carried out using eight gastric cancer tissues and normal gastric mucosae. We selected 53 genes up-regulated in gastric cancer compared to normal gastric mucosae from our microarray data set, and, among these, identified five candidate marker genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) which were not expressed in peripheral blood mononuclear cells (PBMCs) from 4 healthy volunteers. We further carried out semi-quantitative nested reverse transcription-polymerase chain reaction (RT-PCR) for HRH1, EGFR, CK20 and CEA in addition to the five newly identified genes using PBMCs of patients with gastric cancer, and found that expression of one or more genes out of the nine was detected in 80% of the patients with gastric cancer. Moreover, the numbers of genes expressed in PBMCs were ≤2 and ≥2 in all vascular invasion-negative cases and in 5 of 6 positive cases, respectively, showing significant differences between the two groups (P=0.041). Nested RT-PCR analysis for the set of nine marker genes using PBMCs may provide the potential for detection of circulating gastric cancer cells prior to metastasis formation in other organs.
Introduction
Gastric cancer causes approximately 800,000 deaths worldwide per year and is still one of the leading causes of cancer-related death in the world (1) . Most gastric cancers at an early stage can be cured by surgical resection; however, patients with advanced gastric cancers have worse prognosis than those with early stage disease (2) . Although metastasis or relapse is the main cause of death for patients with gastric cancer (3), the hematogenous spread of malignant cells remains undetected at the time of initial therapy. During the development of cancer, tumor cells may detach from the primary tumor and disseminate into the lymph system and/ or blood circulation, and grow in the bone marrow, liver, kidney and other organs, which is called micrometastasis (4) . Micrometastasis is barely detected by routine biochemical and histopathological assays or graphical methods, such as X-ray, CT and MRI (3) . Detection of circulating tumor cells at the mRNA level [reverse transcription-polymerase chain reaction (RT-PCR)] in blood samples of patients with cancer could serve as a unique and easy diagnostic tool to predict cancer recurrence and to monitor treatment effectiveness (5) (6) (7) . However, molecular marker(s) that detect circulating gastric cancer cells for routine clinical use have not yet been identified. Hence, the development of novel diagnostic molecular marker(s) to detect circulating gastric cancer cells is an issue of great clinical importance.
Carcinoembryonic antigen (CEA) is a well-known tumor marker and has been used to detect small amounts of adenocarcinoma cells in the blood, peritoneal wash or other body fluids (8) (9) (10) (11) (12) . However, the expression of CEA mRNA is not specific to cancer cells and often produces false-positive results (13) . Profiling of gene expression patterns on genome-wide microarrays enables investigators to perform comprehensive characterization of molecular activities in cancer cells (14) (15) (16) (17) . Systematic analysis of expression levels for thousands of genes is also a useful approach for identifying molecular markers to detect small amounts of circulating cancer cells (18) . In this study, we identified genes whose expression had been altered during gastric carcinogenesis using genome-wide information obtained from 8 cases on a microarray consisting of 30,000 transcribed elements. Based on the results of the microarray assay, we identified five candidate genes for the specific detection of circulating gastric cancer cells at the mRNA level. We suggest that such information may lead ultimately to improve the prognosis of patients with gastric cancers.
Materials and methods
Blood and tissue samples. Blood samples were obtained from 10 patients with gastric cancer who underwent laparotomy and 4 healthy volunteers after obtaining informed consent. Heparinized blood samples (5 ml) from the 10 patients with gastric cancer were obtained from a peripheral artery through a catheter used for monitoring arterial blood pressure during surgical operation. Peripheral venous blood was obtained from 4 healthy volunteers for control after discarding the initial 10 ml of blood to protect the mixture from epithelial cells. Clinicopathological characteristics of the 10 patients are shown in Table I . Clinical stage of each patient was judged according to the Union for International Cancer Control (UICC) TNM classification. Among the 10 patients with gastric cancer, 8 primary gastric cancer tissues and corresponding non-cancerous gastric mucosae from surgically resected tissues were obtained at Sapporo Medical University and Douto Hospital after each patient had provided informed consent. The samples that had been confirmed histologically as gastric adenocarcinoma were used for microarray study. These samples were immediately frozen and stored at -80˚C. All cancer tissues were obtained from the margin of the tumor mass, while non-cancerous tissues were obtained from corresponding normal mucosae of the same stomach. This study was approved by the Ethics Committee of Sapporo Medical University, School of Medicine, Hokkaido, Japan.
RNA extraction of blood samples. We prepared peripheral blood mononuclear cells (PBMCs) using Ficoll (Amersham Biosciences, Buckinghamshire, UK) and extracted total RNA using TRIzol (Invitrogen, Inc., Carlsbad, CA, USA) according to the manufacturer's instructions. Before the synthesis of cDNA, deoxyribonuclease I (DNase I) (Nippon Gene, Japan) was added to each sample of total RNA according to the manufacturer's instructions.
Analysis of microarray.
Total RNA was extracted from each gastric tissue using TRIzol according to the manufacturer's instructions. To guarantee the quality of RNAs, total RNA extracted from the residual tissue of each case was electrophoresed on a denaturing agarose gel, and the quality was confirmed by the presence of rRNA bands. After treatment with DNase I, T7-based RNA amplification was carried out as described previously with a few modifications (19) . Using 5 µg of total RNA from each tissue sample as starting material, one round of amplification was performed; the amount of each amplified RNA (aRNA) was measured by a spectrophotometer. A mixture of normal gastric mucosae from 8 patients was prepared as a universal control and was amplified in the same manner; 2.5 µg of aRNAs from each cancerous tissue and from the control was reversely transcribed in the presence of Cy5-dCTP and Cy3-dCTP, respectively (15) . AceGene 30K-1 Chip Version (Hitachi Software Engineering Co., Japan) was used for microarray analysis. The procedures for hybridization, washing, photometric quantification of signal intensities of each spot and normalization of data were according to the manufacturer's instructions. To normalize the amount of mRNA between tumors and controls, the fluorescence intensities of Cy5 (gastric cancer) and Cy3 (control) for each target spot were adjusted so that the mean Cy5/Cy3 ratio of 30,000 genes equaled 1. Genes were categorized into three groups according to the cancer/normal ratio of their mean signal intensity: up-regulated (expression ratio >5.0), downregulated (expression ratio <0.2) and unchanged expression (expression ratio between 0.2 and 5.0).
Semi-quantitative RT-PCR.
To validate the result of the microarray analysis, we examined the expression levels of the genes up-regulated in gastric cancer by means of semiquantitative RT-PCR analysis. Total RNAs (3 µg) extracted from each cancerous tissue and normal gastric mucosa were reversely transcribed for single-stranded cDNAs using oligo(dT)12-18 primer with Superscript II reverse transcriptase (Life Technologies, Inc.). Each single-stranded cDNA was diluted for subsequent PCR amplification. A housekeeping gene, GAPDH, served as the internal control. The PCR reaction was conducted at 95˚C for 5 min, and then for 30 cycles at 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 1 min followed by 72˚C for 10 min, in the Gene Amp PCR System 9700 (Perkin-Elmer Applied Biosystems, Foster City, CA, USA).
Nested RT-PCR using blood samples. We performed nested RT-PCR using total RNAs extracted from PBMCs to accurately examine mRNA levels of the candidate marker genes. Initially, RT-PCR was carried out as described above. In nested RT-PCR, 1 ml of the initial PCR product, 4 ml of 10X PCR buffer, 200 mmol/l dNTP mixture, 0.2 mmol/l primers and 1 unit Taq DNA polymerase (Takara) were added to a 40-ml aliquot of the reaction mixture. The PCR reaction was conducted at 95˚C for 5 min, and then 30 cycles at 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 1 min followed by 72˚C for 10 min, in the Gene Amp PCR System 9700. The RT-PCR products were detected using 2% agarose gel Table II .
Results

Identification of up-or down-regulated genes in the gastric
cancers. We extracted RNAs from eight primary gastric cancer tissues and corresponding normal gastric mucosae as control, and carried out gene expression analysis using a microarray consisting of 30,000 genes or ESTs. We then selected genes from our data set according to the criterion that the cancer/ normal ratio of the mean signal intensity of a given gene was >5.0 or <0.2, and 53 genes were identified as up-regulated and 123 genes as down-regulated in the gastric cancer tissues compared to the normal gastric mucosa (Tables III and IV Identification of candidate genes as molecular markers for the detection of circulating gastric cancer cells in human peripheral blood. Of the 53 genes that were up-regulated in the gastric cancer compared to the normal gastric tissues, we identified five candidate marker genes [tetraspanin 8 (TSPAN8), epithelial cell adhesion molecule (EPCAM), matrix metallopeptidase 12 (MMP12), matrix metallopeptidase 7 (MMP7) and regenerating islet-derived 3 α (REG3A)] for the detection of circulating gastric cancer cells in peripheral blood in accordance with the following criteria: i) no or weak expression in human normal tissues in the published database (20) , ii) no expression in PBMCs from 4 healthy volunteers by nested RT-PCR. In addition to the above five newly identified genes, we analyzed histamine receptor H1 (HRH1) since a previous study reported that this gene was overexpressed in gastric cancer cells, and the expression of this gene satisfied the above criteria (21) . Moreover, three candidate marker genes [keratin 20 (CK20), epidermal growth factor receptor (EGFR) and carcinoembryonic antigen (CEA)], which have been reported to be promising markers for the detection of cancer cells, were further analyzed (11, 13, 22, 23) .
Association of the expression of the nine marker genes for the detection of circulating gastric cancer cells with clinicopathological parameters by nested RT-PCR.
We carried out semi-quantitative nested RT-PCR analysis of the nine candidate marker genes for the detection of circulating cancer cells using PBMCs of patients with gastric cancer. Of the nine candidate genes, the expression of MMP12 and CEA mRNAs was positive in 40% of the patients with gastric cancer. However, the expression of the other seven genes was positive in ≤30% of the patients, respectively (Table V) . We then investigated a combined effect of the expression of the nine genes on the detection of circulating cancer cells. Expression of one or more genes out of the nine was detected in 80% of the patients with gastric cancer by nested RT-PCR (Table VI) . We further investigated the association of the expression of the nine candidate marker genes with clinicopathological parameters of the 10 cases. We focused on four parameters: vascular invasion (v factor), lymphatic invasion (ly factor), lymph node metastasis (N factor) and pathological stage I-IV, and investigated the association of these parameters with the total number of positive genes in the PBMCs of each patient (Fig. 1) . Of the four parameters, the numbers of genes expressed in the PBMCs were ≤2 in all of the vascular invasion-negative cases (v 0), while the numbers of genes were ≥2 in 5 of 6 positive cases (v 1-3), exhibiting a significant difference between the two groups (P=0.041; Fig. 1A ). However, no significant association was observed for the other three parameters (Fig. 1B-D) , suggesting that the combined expression analysis of the nine marker genes using PBMCs detected micrometastasis through vascular invasion in the primary gastric cancer tissues. 
Discussion
Microarrays, at present, are widely used to analyze expression of thousands of genes simultaneously in cancer tissues. In the present study, we identified five genes (TSPAN8, EPCAM, MMP12, MMP7 and REG3A) as potential markers for the detection of circulating cancer cells in the peripheral blood of patients with gastric cancer through genome-wide gene expression profiling in combination with nested RT-PCR. Some of these genes have previously been reported to be up-regulated in gastric cancer cells; however, they have not previously been designated for the detection of circulating gastric cancer cells by nested RT-PCR. Furthermore, the combined expression analysis of the five genes and four previously reported marker genes, HRH1, EGFR, CK20 and CEA, revealed that one or more mRNAs among the nine genes could be detected in 80% of the patients with gastric cancer by nested RT-PCR, suggesting that a set of nine marker genes is more sensitive than a single marker gene for detection of circulating gastric cancer cells. In this study, we did not investigate the association of distant metastasis with expression of the nine marker genes since no patients had distant metastasis among the 10 studied patients. Although we could not exclude false-positive cases due to non-malignant epithelial cells which may have contaminated the blood samples during collection and which may have expressed the targeted transcripts (18), pathological v factor showed a significant association with the total number of marker genes expressed in the PBMCs of the patients. Hence, the set of nine marker genes may be promising for the detection of minimal amounts of circulating gastric cancer cells prior to the metastatic growth of gastric cancer cells in organ(s). Among the five marker genes which were newly identified in the microarray analysis, we identified epithelial cell adhesion molecule (EPCAM) which is a member of a family of type I membrane proteins and pan-epithelial differentiation antigen expressed in many types of carcinomas (24-28).
Magnetic beads or structures coated with EPCAM monoclonal antibodies have been recently used for circulating cancer cell separation (29) (30) (31) . Although we did not compare the accuracy of the detection of gastric cancer cells by these methods to that of nested RT-PCR since we did not conduct the former assays, 30% of patients with gastric cancer exhibited EPCAM-positivity in PBMCs by nested RT-PCR. Further clinical study investigating the relationship between the clinical outcome of patients and EPCAM expression in PBMCs by nested RT-PCR may clarify whether this method could be clinically applied for the detection of circulating gastric cancer cells. Two matrix metalloproteinases, MMP7 and MMP12, were among the five marker genes which were newly identified in this study. MMPs are a family of zinc-dependent proteolytic enzymes capable of cleaving extracellular matrix proteins, and the expression of MMPs in cancer tissue has been reported to be associated with the risk of metastasis (32) (33) (34) (35) (36) (37) (38) . These two MMPs may play important roles in tumor invasion and the formation of metastasis in gastric cancer.
In conclusion, five novel marker genes were designated for the detection of circulating gastric cancer cells. The nested RT-PCR analysis for the set of nine marker genes, TSPAN8, EPCAM, MMP12, MMP7, REG3A, HRH1, EGFR, CK20 and CEA, using PBMCs of patients with gastric cancer may provide the potential for the detection of circulating gastric cancer cells prior to the formation of metastasis in other organs. Our data suggest that early detection and personalized therapy for gastric cancers, by prescribing the appropriate treatment to patients with a high risk of metastasis, may be achievable by utilizing specific sets of marker genes according to the approach shown here. 
